New recombinant glycosylated prourokinase for treatment of patients with acute myocardial infarction  by Weaver, W.Douglas et al.
1242 JACC Vol. 24, No. 5 November I. 1094:124%! 
W. DOUGLAS WEAVER, MD, FACC, JOSEPH R. HAR 
mbolytic drug with l~~i~~@ 
ma was collected serially to measure fibrinogen, plas- 
brambin antithrombln III and ~b~no~ptid~ A. Clin- 
e coronary artery patency rate at min was similar 
imens, averaging 73% (95% confidence inte~uI 
The current focus in thmmholytic drug development has been 
on defining treatment s rategies that result in a high and rapid 
rate of arterial patency, especially Thrombolysis n~yoc:trd~al 
Infarction (TIMI) grade 3 flow, and a low rate of reoccbdon 
and stroke (l-6). Despite the proved benefit of currently 
available drugs, each has limitations. These include less than 
perfect lysis, failure to rapidly and reliably establish full TIMI 
grade 3 Row in ?SO% of patients, the unpredictable occur- 
rence of reocclusion i  6% to 15% of patients after treatment 
and the occurrence of hemorrhagic strake (3.7-12). Though 
relatively more effective than streptokinase in restoring pa- 
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tency within 60 to 90 min of treatment, alteplase has been 
ruported in some studies (hl-13) to be itss~iated with both 
more frequent reocclusion after treatment and a bigher ate of 
helnorrhagic strzlke, espe~ial!y ir . . th: Lderly. The higher rate 
of reocclusion after alteplase treatment results in coronary 
artery patency nearly equivalent to that achieved with strep- 
tokinase by 24 h (3). Both reocclusion and failwre to rapidly 
reestablish TIMI grade 3 Row are angiographic events that 
have been shown to be associated with adverse clinical events, 
including a higher ate of death, reinfarction and congestive 
heart failure (3,13,14). Recently, it has been determined 
(15-18) that both ctreptokinase and alteplase treatments i:re 
associated with secondary thrombin and platelet activation 
Activation of coagulation factors by thrombolytic ireaimenl 
may, in turn, cause reucclusion of a successfully re~a~ali~ed 
artery by stimulating thrombosis both in the area of damaged 
intima and on the surface of incompletely sed clot (19,20). 
An agent or treatment regimen with a lower ate of reocclusion 
would be likely to result in improved clinical ontcome. 
Prourokinase, a single-chain urokinaje-type plasminugen 
activator, is a unique thrombolytic drug in that it is a naturally 
occurring inactive zymogen. Inactive, single-chain prouroki- 
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The resultmg mcrease 
which cauSeS fibri 
of more clot-boun 
oyed a ~ecor~binant, uong~ycosy~ated 
form of ~~ou~ok~~ase givenat a dose of 80 mg to 198 patients 
with acute myocardial infarction (35). This dose of an ungly- 
cosylated prourokinase caused a large dscrease in circulating 
fibrinogen, nearly as great as that observed with streptokinase. 
The arterial patency rate at 90 min was 71% and there qE’as a 
5% reocclusion rate in the subset of 121 paiients who were 
restudied. This relatively low rate of reocclusion was Nought o 
be possibly related to the extensive fibrinogen0 and ad- 
junctive trcatme~t with intravenous beparin (36). or bieed- 
ing was common, occurring in 14% of patients, primarily 
around arterial puncture sites. 
The purpose of the present study was to test the effect of 
two dosages, 60 and 80 mg, of ir novel recombinant form of 
glycosylated prourokinase (A-74187) in patients with acute 
myocardial infarction, and in a third group of patients to 
determine the effect of priming by infusing a bolus of 250,000 
111 of recombinant urokinase intravenously just before treat- 
ment with prourokinase. Efficacy measures included arterial 
patency rate at 90 min and coagulation variables. 
atienis. Patients with suspected acute myocardia! infarc- 
tion at each of the participating centers were evaluated for 
possible inclusion in the c+ady. In essence, patients were 
considered eligible for study if they had typical symptoms with 
a duration of 56 h, were aged 575 years, had ST segment 
elevation (~1 mm in two limb leads or ~2 mm in two 
contiguous V leads) on the initial electrocardiogram (KG) 
ding or stroke. After giving 
s were s~~~c~t~a~~y assigned 
Sing protoco!s: I) an initial 
of the dosage of ~rourok~uase 
remainder infused over 90 min. 
100 s for at least he next 48 h. 
at baseline and at 3, 6, 12, 18 a 
deterrninati~~n of levels of fibrinogen 
bin aut~tbrombi~ III. T~RYI&M nntithro 
either 80-mg monotherapy or the W-mg primed dose. Assays 
of these coagulation markcrs were performed oy a core 
laboratop without knowledge of trzatment assignment. All 
treatments 10r recurrent pain and c*mqAications of acute 
infarction. as well as ther diagnostic tests and procedures, 
were performed at th iscretion of the ciinical investigator. 
coronary angiography at 60 min (if 
in to determine arterial patency; the 
s the primary end point in the study. 
Coronary patency and flow grades were classified according to 
TIMI criteria and determined from the first coronary injection 
by subsequent review of the cineangiographic films by the 
investigators, who had no knowledge of treatment assignment 
for the last two-thirds of the study (38). 
In those patients in whom the infarct-related artery re- 
mained occluded (TIM: flow grade 0 or 1) at 90 min, patency 
could be established by administration f an additional 25O$OO 
IU of intracoronary urokinase or by balloon angioplasty. or by 
both. In patients with arterial patency at 90 min (TIMI grade 
2 or 3) after treatment with prourokinase. a 
(range 18 to 30 h) angiogram was performed 
ble. Evidence of bleeding, recurrent ischemia, reinfarction and 
stroke was assessed daily until hospital discharge i)r al 14 days, 
whichever occurred earlier. Recurrem ischernia W?s ch?rXter- 
ized by a spontaneous recurrence ofsymptoms htillg 220 min 
in association with new EKG changes. Keinfarction was de- 
fined by evidence of recurrent pain associated with subsequent 
new Q waves or reelevation of the creatine kinase enzymes 
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Table 1. Baseline Characteristics and In-Hospital Events in Patients Treated by Each of the 
Prourokinase Dosage Regimens 
60-q mmg SO-mg 
Monotherapy +rJJIc ~~notherapy All 
(n = 36) [n = 40) (fl = 42) (n = 1%) 
___~.__ 
Lkmographic data 
Male (a) 
Age (yr) 
Clinical history (%) 
Angina 
Myocardial infarction 
Hypertension 
Ix&etcs 
Smakcr 
Duration of symptomr (II) 
Inkrct Iocatiun (by EC(i) (?I 
Antsrior 
Inferior other 
W!modyfliunic vitriahlo 
Initiid brnrt riw (hout\.‘min) 
laitinl hkhd prewirc (mm I?@ 
Itlfilrctdded iWtL’1)’ (‘; 1 
LAD 
UCA 
LC?i 
In-hospitrl wcnts (‘;) 
Recurrwt ischcmia 
Heinfarction 
Major bleeding” 
Stroke 
Death 
01 
532 12 
83 
57 i: 9 
33 
20 
511 
57 
43 
53 
4s 
hl 
33 
6 
after recurrent symptoms. Rates of tttijor bkcditig requiting 
blood transfusion unrelutcd to cardtao s~~r~ery were also 
tabulated. 
The study was reviewed and ~~~~rovcd by the ~~rn~~n 
Suhjccts Review Committre of each participating hospital. 
ikrcnces between treatment groups were compared by using 
chitsquare analysis. the Fisher exact test or repeated measures 
of analysis of variance. The 95% contidcnce limits arc reported 
for both arterial patency and reocciusion. Fibrinogen and 
plasminogen levels are reported as a mean change over time 
from the baseline value. Values are reported only for patients 
who had both a known baseline value and no more than one 
missing serial obsetvtttion, In similar fashion, the absolute 
levels of fibrinopeptide A and thrombin antithrombin 111 are 
reported. The latter test result was available in only the last 43 
patients studted in the ri~ndotnized protocol. 
dut~tion of synlptoms before treatment averaged 2.4 + 1.1 h. 
There were few differences in baseline characteristics among the 
three treatment groups, except for a slightly greater incidence of 
prior myocardial infarction in the W.,tg monotherapy grolap. 
Among patients studied, the infarct-related artery was the left 
anterior descending coronary artery in 4g’;i, the right coronary 
artery in 40% and the left circumflex artery in 13%. Heparin was 
infused for an average of 92 :t 53 h (dth. 75th percentile 66, 
120 h). The median activated partial throm~~lastin time was 81 s 
at 12 h (25th. 75th percentile 49, I14 s). Forty percent of patients 
did not consistently achieve an activated partial thromboplastin 
time >41) s throughout the 1st 24 h. Details of the baseline 
characteristics for each patient group are shown in Table I ~ 
Arterial patency rates. The overall arterial patency rate at 
90 min for all 128 patients \Has 73% (9S% CI 64% to 80%). 
There was no difference m the rate among patients who 
rercived 60.mg or SO-mg pr~~~~o~i~ase rn~~~ot~~ra~y or the 
primed 60.mg dose (Fig. 1). TlMI grade 3 flow rates were also 
similar for all three regimens, averaging 52% (95% CI 42% to 
61%). 
seline characteristics. There were 12s pa- 
tients with acme myocardial infarction studied. Forty-six (36%) 
were treated with 60 mg of prourokinase alone, 42 (33%) were 
treated with So mg of prourokinase alone, and 40 (31%) received 
Anm1g the 7’) puticants aV;aiMc for ~~~~~~~~~~~~~~~y ial Alb min, 
the W.33~~ pi\te!lCy WC WilS 62’; (95’? CT s(jc/i’ to 73’ii,) (Fig. 
1). Although the OO-min patency rate for the primed regimen 
appears lower, the confidence limits overlap rates in the othra 
groups and thus this may he a chance finding. However. it 
could IpfIccs the S- to l~hill delay between the holus of 
recombinant urokinase and initiittion of the idusion of 
pronrokinase in the primed regimen. Thai is, the patients 
treated with monotherapy received more of the infusion of 
prourokinase sooner, and the (,(I-min angiogram may reflect 
this dose-time effect. In contrast to experimemal studies, the 
1 study showed no ct 4drnce that priming enhanced the effcctivc- 
ness of prourokinase. There were also no diffcrcnccs in 
patency among the three coro~ra~y art&s (Table 1). 
In the 35 patients whose arteries were occluded at 90 rrh, 
1 arteries opened spontaneously a few minutes later. 3 of 14 
arteries opened after an additional intracoronary infusion of 
2SO,O(4Q I&r of urokinase and 20 (91%) of 22 arteries were 
opened by “rescue” coronary angioplasty. Eight other patients 
with occluded arteries at 90 min were treated co11 ::rvatively 
either because of the arterial location of the thromhus or 
because the occlusion was believed to represent an insignifi- 
cant threat to the patient. There were 70 patients with TM 
grade 2 to 3 flow at 9ll min l’hose coronary artery patency was 
reevaluated at 24 h to determine whether it had been main- 
tained. only one patient (1.4%, 95% CI 0.1% to 4.1%) showed 
evidence of arterial reocclusion. The reason the remaining 
patients were not restudied was related primarily to physician 
discreiion at particular sites and not to clinical event rates. 
ital events. With the exception of recurrent chest 
pain, which was noted before hospital discharge in 15% uf 
patients, clinical events were unusual after treatment with 
prourokinase. The single death (1%) was due to myocardial 
failure that occurred almost immediately after the start of 
trea;ment; there were no strokes and 7% of patients required 
transfusion. Three patients (2%) developed clinical evidence 
01‘ Wi~lfilKtiOll ;iftr‘r treatment. By the time of 
charge, 45 patients (35%) had had coronary angioplasty per- 
formed. mcluding 22 as a rescue procedure, and 13 patients 
f 10%) had coronary bypass surgery. 
~~a~u~a~~~~ variables. Fibrinogen and ~~~~su~iu(~gcn levels 
reached a nadir at 3 to 4 h after treatment and returned to 
baseline levels by 24 h. The X0-mg prourokinase dose resulted 
in a greater ccnsumt;tion of fibrinogen than did the 60-mg dose 
(i.e.. to 59 I 5% of the baseline value compared with 76 “r 
5.5%). Alpha,-antiplasmin lcvcls wcrc lowest (40.3 t 2,Ol;j~f 
3 h after initiation of treatment and the decrcasc was similar 
for all three dosages. Fibrinopeptide A levels were highest at 
the time of inrtiation of prourokinase and declined rapidly in 
the 1st 6 h. Thrombin antithrombin IPI levels were elevated in 
most patients at baseline, increased slightly at 3 h and then 
changed littlc throughout day 1 (Fig. 2). There was no differ- 
cnce in the baseline level of either fibrinopeptide A (30.8 i- 6.8 
vs. 20.3 ir 4.0 nglml) or thrombin antithrombin 111 (IO.4 t 5.3 
vs. 12.4 5 3.4 nglml) in patients without reperfusion at 90 min 
versus those with a patent artery. 
A-74187 is a recombinant glycosylated form of pwuroki- 
nase cloned and expressed in mouse hybridoma cells. We 
believe that this study is the first clinical dosing evaluation of 
this new thrornbolytic agent. Two doses, 60 tug and 80 mg, 
were studied, as was the effect of “priming.” using an initial 
bolus dose of 250,000 IU of recombinant urokinase. Priming 
was tested on the basis of ohservations from experimental 
sm&:s (28-31) in which the activation time and clot lyis lime 
of orourokinase could be signi~ca~ltly enhanced by using a 
smah bolus of citlicr urokinasc or tissue plasminogen activator 
b~&ve treatment with p~ourokinase. 
‘The overall 90-min arterial patency rate for all regimens 
tcsicd averaged 73% (95% Cl 64% to 80%); and TliVl grade 
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Fibrinogen PLasmfnoaen 
0 
HOW 
3 flow averaged 52% (95% CI 42% to 61%) with no d~~ere~~ces 
among the three regimens. The TIM1 grade 3results obscrvcd 
here are similar to those in angiographic studies of alteplase 
(3,7,9,39-41). Unlike the experimental setting in wbic~ 
prouraldnase i  associated with a lag phase and slow onset of 
clot lysis, the fiO_min patency rate. of 63% (95% C8 50% to 
73%) bnd 52% TIM1 grade 3 flow rates at ()I) min 
reletE,ely rapid clot lysis. For comparison, a stznd 
infusion of alteplase r sults in a BO-min patency rate of 62% 
and the “ant-1~ded” dose of alteplase a 74% rate, all within 
the same confidcuce limits (39). There was no increment in
min or 90-min a~essm~nt) by 
250,OOO IU of recombinant 
s is contrary to experimental observations and 
may reflect species differences or cou the result of an 
insufficient dose OS recombinant urokin overcome circu- 
lating inhibitors. The finding might also indicate that dosages 
are above athreshold inwhich priming is important. 
ative but secondary finding of the study is the 
relatively low 24-h reocclusion rate of 1.4% (95% CI 0.1% to 
which compares favorably with that of other agents and 
ns. Specifically, the teocclusion rate for front-loaded 
ressive intravenous heparin regimen has 
bc 7.8%. In earlier studies, reocclusion 
rates after alteplase treatment were even higher; a finding 
consistent with the mounting evidence that the currently 
available drugs expose both injured endothelium and clot- 
bound thrombin, resulting in increased levels of thrombm 
activity after treatment that may lead to reocclusion (42-47). 
The low rate of reocclusion bserved in these patients is also 
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2. Fibrhog~n. plasminogen, 
main ~titbrom~m IIH and I% 
b~no~~t~de A levels at baseline and 
for 24 h after treatment with 
pourokinaSe (broad). 
2 SE are shown for 36 patients 
receiving 6&mg ~ro~ro~n~ mono- 
therapy, 32 patients receiving 8Q-mg 
monotherapy and 30 patients receiv- 
available for 43 and 91 patienrs, re- 
A kve.vClS WIOQ dOSh& 
brino~~tide A lcvelsre 
baseline and lowest at 3 h and then 
to increase throu~h~at the 
ere was an increase in throm- 
bin ant~thrombin IIP Ievek at 3 h. 
Intravenous hepin was adminis- 
tered throughout the 1st 24 h. 
Ie when combi~cd with the results of ot 
ies. Among the patients assessed for 
this and prior prourok 
ical i~t~~c~t~~l~s acre 
to 2.I%) of 328 arter$es re
re~cIMsion needs to be confirmed inmore patients. It could be 
of significant clinical im~rtaRce; for example, the rate of 
reocclusion after prourokinase treatment may be similar to 
that observed when alteplase is administer 
antithrombin agent ~a~icMlarl~ effective in
sioa (47,50). The c~agulatio~ endings 
A-74187 form of pr~~ro~~as~ al o differ from those of 
prourokinase regimens in uvhich t ere was extensive s co 
depletion of fibrinogen (35). The consistent low rate of reoc- 
elusion among studies suggests hat factors other than exten- 
sive fibrinogen depletion are responsible for rhe low rate of 
reocclusion, It has recently been shown (51) that prourokinase 
can bind to platelet and endothelial membranes; perhaps, in 
some way such binding protects the artery from reocclusion. 
In this study, the secondary markers ofthrombin activation 
(i.e., thrombin antithrombin 111 and fibrinopeptide A levels) 
were highest at the initiation of treatment and did not rise 
sigoificantly after treatment. There was also no di 
between baseline levels of ~brinope~tide A and thrombin 
antithrombin III levels in patients with patent or occluded 
arteries at 90 mins. Elevated thrombin antit III and 
fibrinopeptide A levels have been shown in studies 
(43-46) to occur after treatment with thrombolytic drugs, and 
they appear to be associated with thrombolytic drug failures 
and reocclusion. The use of greater doses of heparin and 
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